Erdheim-Chester Disease

References

1. 1.↵
   1. Sedrak P,
   2. Ketonen L,
   3. Hou P, et al

   . Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. AJNR Am J Neuroradiol 2011;32:2126–31 doi:10.3174/ajnr.A2707 pmid:21960492

   Abstract/FREE Full Text
2. 2.↵
   1. Oliveira M,
   2. Monteiro S,
   3. Dos Santos J, et al

   . Erdheim-Chester disease: a rare clinical entity. Eur J Case Rep Intern Med 2020;7:001630 doi:10.12890/2020_001630 pmid:32908822

   CrossRefPubMed
3. 3.↵
   1. Todisco A,
   2. Cavaliere C,
   3. Vaglio A, et al

   . Erdheim-Chester disease: a challenging diagnosis for an effective therapy. Clin Neurol Neurosurg 2020;194:105841 doi:10.1016/j.clineuro.2020.105841 pmid:32330799

   CrossRefPubMed
4. 4.↵
   1. Sánchez-Villalobos JM,
   2. Jimeno-Almazán A,
   3. López-Peña C, et al

   . Erdheim-Chester disease mimicking multiple sclerosis or a new association? Mult Scler Relat Disord 2019;30:94–97 doi:10.1016/j.msard.2019.02.008 pmid:30743087

   CrossRefPubMed
5. 5.↵
   1. Pegoraro F,
   2. Papo M,
   3. Maniscalco V, et al

   . Erdheim-Chester disease: a rapidly evolving disease model. Leukemia 2020;34:2840–57 doi:10.1038/s41375-020-0944-4 pmid:32591646

   CrossRefPubMed
6. 6.↵
   1. Cohen Aubart F,
   2. Idbaih A,
   3. Galanaud D, et al

   . Central nervous system involvement in Erdheim-Chester disease: an observational cohort study. Neurology 2020;95:e2746–54 doi:10.1212/WNL.0000000000010748 pmid:32887776

   CrossRefPubMed
7. 7.↵
   1. Garg N,
   2. Lavi ES

   . Clinical and neuroimaging manifestations of Erdheim-Chester disease: a review. J Neuroimaging 2021;31:35–44 doi:10.1111/jon.12785 pmid:32920940

   CrossRefPubMed
8. 8.↵
   1. Abdelfattah AM,
   2. Arnaout K,
   3. Tabbara IA

   . Erdheim-Chester disease: a comprehensive review. Anticancer Res 2014;34:3257–61 pmid:24982329

   Abstract/FREE Full Text
9. 9.↵
   1. Manaka K,
   2. Sato J,
   3. Makita N

   . Neuroendocrine manifestations of Erdheim-Chester disease. Handb Clin Neurol 2021;181:137–47 doi:10.1016/B978-0-12-820683-6.00010-5 pmid:34238453

   CrossRefPubMed
10. 10.↵
    1. Cives M,
    2. Simone V,
    3. Rizzo FM, et al

    . Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol 2015;95:1–11 doi:10.1016/j.critrevonc.2015.02.004 pmid:25744785

    CrossRefPubMed
11. 11.↵
    1. Kumar P,
    2. Singh A,
    3. Gamanagatti S, et al

    . Imaging findings in Erdheim-Chester disease: what every radiologist needs to know. Pol J Radiol 2018;83:e54–62 doi:10.5114/pjr.2018.73290 pmid:30038679

    CrossRefPubMed
12. 12.↵
    1. Caparros-Lefebvre D,
    2. Pruvo JP,
    3. Rémy M, et al

    . Neuroradiologic aspects of Chester-Erdheim disease. AJNR Am J Neuroradiol 1995;16:735–40 pmid:7611030

    PubMed
13. 13.↵
    1. Jeon I,
    2. Choi JH

    . Isolated thoracic intramedullary Erdheim-Chester disease presenting with paraplegia: a case report and literature review. BMC Musculoskelet Disord 2021;22:270 doi:10.1186/s12891-021-04061-7 pmid:33711983

    CrossRefPubMed
14. 14.↵
    1. Berkman J,
    2. Ford C,
    3. Johnson E, et al

    . Misdiagnosis: CNS Erdheim–Chester disease mimicking CLIPPERS. Neuroradiol J 2018;31:399–402 doi:10.1177/1971400917710251 pmid:28685649

    CrossRefPubMed
15. 15.↵
    1. Wang Y,
    2. Camelo-Piragua S,
    3. Abdullah A, et al

    . Neuroimaging features of CNS histiocytosis syndromes. Clin Imaging 2020;60:131–40 doi:10.1016/j.clinimag.2019.10.001 pmid:31874337

    CrossRefPubMed
16. 16.↵
    1. Johnson MD,
    2. Aulino JP,
    3. Jagasia M, et al

    . Erdheim-Chester disease mimicking multiple meningiomas syndrome. AJNR Am J Neuroradiol 2004;25:134–37 pmid:14729543

    Abstract/FREE Full Text
17. 17.↵
    1. Huang Z,
    2. Li S,
    3. Hong J, et al

    . Erdheim-Chester disease mimicking lumbar nerve schwannoma: case report and literature review. Spinal Cord Ser Cases 2019;5:90 doi:10.1038/s41394-019-0234-4 pmid:31700688

    CrossRefPubMed
18. 18.↵
    1. Unadkat BS,
    2. Kashikar SV,
    3. Bhansali PJ, et al

    . Intracranial Rosai-Dorfman disease: a case to remember. Cureus 2022;14:e32605 doi:10.7759/cureus.32605 pmid:36660540

    CrossRefPubMed
19. 19.↵
    1. Cheng X,
    2. Cheng JL,
    3. Gao AK

    . A study on clinical characteristics and magnetic resonance imaging manifestations on systemic Rosai-Dorfman disease. Chin Med J (Engl) 2018;131:440–47 doi:10.4103/0366-6999.225053 pmid:29451149

    CrossRefPubMed
20. 20.↵
    1. Prosch H,
    2. Grois N,
    3. Wnorowski M, et al

    . Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. AJNR Am J Neuroradiol 2007;28:1022–28 doi:10.3174/ajnr.A0509 pmid:17569949

    CrossRefPubMed
21. 21.↵
    1. Cerudelli E,
    2. Gazzilli M,
    3. Bertoli M, et al

    . Erdheim-Chester disease: the power of nuclear medicine imaging. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2020;39:323–24 doi:10.1016/j.remn.2020.01.003 pmid:32616456

    CrossRefPubMed
22. 22.↵
    1. Fasulo S,
    2. Alkomos MF,
    3. Pjetergjoka R, et al

    . Erdheim-Chester disease presenting at the central nervous system. Autops Case Rep 2021;11:e2021321 doi:10.4322/acr.2021.321 pmid:34540726

    CrossRefPubMed
23. 23.↵
    1. Liu SZ,
    2. Zhou X,
    3. Song A, et al

    . Exophthalmos and coated aorta in Erdheim–Chester disease. Rheumatology (Oxford) 2020;59:2651–52 doi:10.1093/rheumatology/keaa022 pmid:32025736

    CrossRefPubMed
24. 24.↵
    1. Hazim AZ,
    2. Acosta-Medina AA,
    3. Young JR, et al

    ; Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Classical and non-classical phenotypes of Erdheim-Chester disease: correlating clinical, radiographic and genotypic findings. Br J Haematol 2022;199:454–57 doi:10.1111/bjh.18422 pmid:36017680

    CrossRefPubMed
25. 25.↵
    1. Emile JF,
    2. Tirabosco R

    , Demicco, Elizabeth. WHO Classification of Tumours Editorial Board. Central Nervous System Tumours. Vol 6. 5th ed. 2021
26. 26.↵
    1. Go RS,
    2. Jacobsen E,
    3. Baiocchi R, et al

    . Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:1277–303 doi:10.6004/jnccn.2021.0053 pmid:34781268

    CrossRefPubMed
27. 27.↵
    1. Munoz J,
    2. Janku F,
    3. Cohen PR, et al

    . Erdheim-Chester disease: characteristics and management. Mayo Clin Proc 2014;89:985–96 doi:10.1016/j.mayocp.2014.01.023 pmid:24814521

    CrossRefPubMed
28. 28.↵
    1. Pan Z,
    2. Kleinschmidt-DeMasters BK

    . CNS Erdheim-Chester disease: a challenge to diagnose. J Neuropathol Exp Neurol 2017;76:986–96 doi:10.1093/jnen/nlx095 pmid:29096034

    CrossRefPubMed
29. 29.↵
    1. Haque A,
    2. Pérez CA,
    3. Reddy TA, et al

    . Erdheim-Chester disease with isolated CNS involvement: a systematic review of the literature. Neurol Int 2022;14:716–26 doi:10.3390/neurolint14030060 pmid:36135995

    CrossRefPubMed
30. 30.↵
    1. Badalian-Very G

    . A common progenitor cell in LCH and ECD. Blood 2014;124:991–92 doi:10.1182/blood-2014-06-581736 pmid:25124781

    FREE Full Text
31. 31.↵
    1. Haroche J,
    2. Charlotte F,
    3. Arnaud L, et al

    . High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosis. Blood 2012;120:2700–03 doi:10.1182/blood-2012-05-430140 pmid:22879539

    Abstract/FREE Full Text
32. 32.↵
    1. Tzoulis C,
    2. Schwarzlmüller T,
    3. Gjerde IO, et al

    . Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes 2015;8:171 doi:10.1186/s13104-015-1135-7 pmid:25926131

    CrossRefPubMed
33. 33.↵
    1. Costa S,
    2. Julião MJ,
    3. Silva S, et al

    . Erdheim-Chester disease: a rare non-Langerhans histiocytosis. BMJ Case Rep 2021;14:e24114 doi:10.1136/bcr-2020-241143 pmid:34588200

    CrossRefPubMed
34. 34.↵
    1. Starkebaum G,
    2. Hendrie P

    . Erdheim-Chester disease. Best Pract Res Clin Rheumatol 2020;34:101510 doi:10.1016/j.berh.2020.101510 pmid:32305313

    CrossRefPubMed
35. 35.↵
    1. Diamond EL,
    2. Durham BH,
    3. Haroche J, et al

    . Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016;6:154–65 doi:10.1158/2159-8290.CD-15-0913 pmid:26566875

    Abstract/FREE Full Text
36. 36.↵
    1. Arnaud L,
    2. Hervier B,
    3. Néel A, et al

    . CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:2778–82 doi:10.1182/blood-2010-06-294108 pmid:21239701

    Abstract/FREE Full Text
37. 37.↵
    1. Veyssier-Belot C,
    2. Cacoub P,
    3. Caparros-Lefebvre D, et al

    . Erdheim-Chester disease: clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996;75:157–69 doi:10.1097/00005792-199605000-00005 pmid:8965684

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Diamond EL,
    2. Subbiah V,
    3. Lockhart AC, et al

    . Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, open-label VE-BASKET study. JAMA Oncol 2018;4:384–88 doi:10.1001/jamaoncol.2017.5029 pmid:29188284

    CrossRefPubMed